A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Inclusion Criteria:
Exclusion Criteria:
Ocular Exclusion Criteria (Study Eye):
Ocular Exclusion Criteria (Both Eyes):
Capital Federal, C1120AAN, Argentina
Capital Federal, C1122AAI, Argentina
Vienna, 1090, Austria
Mainz, 55131, Germany
Udine, Veneto 33100, Italy
Kazan', 420012, Russia
Moscow, 119435, Russia
Samara, 443068, Russia
Bratislava, 851 07, Slovakia
Ankara, 06490, Turkey (Türkiye)
Istanbul, 34093, Turkey (Türkiye)
Gloucestershire, GL1 3NN, United Kingdom
Liverpool, L7 8XP, United Kingdom
Middx, UB8 3NN, United Kingdom